Drug intelligence / Profile preview

IgY-102

Development stage: Preclinical
Lead developer: IGY Immune Technologies & Life Sciences
Modality: Antibody-Based Therapeutics
Administration: Intranasal

Overview

IgY-102 is a broad-spectrum polyclonal avian IgY antibody candidate being developed by IGY Immune Technologies & Life Sciences for the treatment and prevention of influenza. The product is derived from the egg yolks of hens immunized with influenza antigens, resulting in a diverse population of antibodies (IgY) that can recognize and neutralize multiple strains of the virus. By binding to viral particles, IgY-102 aims to block viral entry into respiratory epithelial cells, providing a passive immunity approach that could be effective against seasonal and emerging pandemic strains. It is currently in the discovery stage of development.

Targets

Flu (Influenza surface proteins)

Beyond the preview

Go deeper on IgY-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IgY-102.

Explore the full profile